Back
Top 3%
17.6%
Top 1%
14.5%
Top 2%
7.7%
Top 0.8%
6.4%
Top 72%
6.4%
Top 2%
6.4%
Top 3%
5.0%
Top 63%
4.1%
Top 5%
1.9%
Top 3%
1.9%
Top 3%
1.9%
Top 3%
1.9%
Top 4%
1.5%
Top 0.7%
1.3%
Top 0.2%
1.3%
Top 3%
1.3%
Top 5%
1.0%
Top 24%
0.9%
Top 5%
0.9%
Top 10%
0.7%
Top 14%
0.7%
Top 18%
0.7%
Top 7%
0.7%
A pretreatment T cell signalling score identifies clinical pembrolizumab response in non-small cell lung cancer patients
2026-02-05
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundImmune checkpoint inhibitors (ICIs) targeting the programmed death (ligand)-1 (PD-1/PD-L1) axis, like pembrolizumab, have significantly improved survival in non-small cell lung cancer (NSCLC). However, less than 50% of patients respond. Identifying early-response biomarkers is crucial to personalize therapy, thereby preventing ineffective, expensive and potentially harmful treatment. MethodsWe applied a novel ex vivo immunopharmacological bioassay to assess pembrolizumab-dependent T c...
Predicted journal destinations
1
Nature Communications
483 training papers
2
Cancers
57 training papers
3
eLife
262 training papers
4
Clinical Cancer Research
22 training papers
5
PLOS ONE
1737 training papers
6
Frontiers in Oncology
34 training papers
7
Frontiers in Immunology
140 training papers
8
Scientific Reports
701 training papers
9
Proceedings of the National Academy of Sciences
100 training papers
10
iScience
74 training papers
11
Cancer Medicine
17 training papers
12
British Journal of Cancer
22 training papers
13
BMC Cancer
21 training papers
14
Cell Reports
25 training papers
15
EMBO Molecular Medicine
15 training papers
16
Journal of Clinical Investigation
50 training papers
17
Cell Reports Medicine
49 training papers
18
JAMA Network Open
125 training papers
19
International Journal of Molecular Sciences
39 training papers
20
Nature
58 training papers
21
PLOS Computational Biology
141 training papers
22
Nature Medicine
88 training papers
23
Communications Medicine
63 training papers